Pharma-biotech pairings continued apace in the antibody-drug conjugate (ADC) space, with 2023 capped by Legochem Biosciences Inc. signing a $1.7 billion licensure deal with Johnson & Johnson arm ...

Synaffix, a Lonza company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), licensed its ADC technology to BigHat Biosciences ...

The very first antibody-drug conjugates (ADCs) to enter clinical evaluation sought to improve the therapeutic index of approved anti-cancer drugs, such as doxorubicin and vinblastine, by linking them ...

Multiple sessions at ESMO Congress 2024 covered antibody-drug conjugates (ADCs), which are an emerging therapy that holds great promise in cancer but comes with challenges. Antibody-drug conjugates ...

Antibody-drug conjugates (ADCs) have reshaped the cancer treatment landscape across a variety of different tumor types. ADCs' peculiar pharmacologic design combines the cytotoxic properties of ...

Lugano/Berlin 18 October 2025 - In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs) ...

Debiopharm ( a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, will release groundbreaking new data at ...

The role of multiplexed ADCs in process control. Technical advantages of modern multiplexed ADCs. How to choose the right multiplexed ADC. Deployment tips for process-control applications. As ...

Managing Adverse Effects Associated With Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer: A Synthesis of Clinical Trial and Real-World Data The present article reviews the current evidence ...

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza's commitment to helping customers deliver ...